Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHB4 | P54760 | 1/20 | 0.64 |
| ▸ | IGF1R | P08069 | 2/20 | 0.53 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.51 |
| ▸ | EGFR | P00533 | 2/20 | 0.51 |
| ▸ | CLK1 | P49759 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | LCK | P06239 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | BRD4 | O60885 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 2/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | FLT3 | P36888 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CDK4 | P11802 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6481335 | 0.88 | EPHB4 (0.55) | EPHB4IGF1RABCG2EGFRCLK1 | |
| SCHEMBL6495796 | 0.88 | EPHB4 (0.55) | EPHB4IGF1RABCG2EGFRCLK1 | |
| SCHEMBL17630793 | 0.85 | MAPK8 (0.53) | EPHB4IGF1REGFRKDRAURKB | |
| SCHEMBL13326018 | 0.84 | MAPT (0.59) | EPHB4ABCG2MAPTGAANPC1 | |
| SCHEMBL4946510 | 0.84 | EPHB4 (0.69) | EPHB4IGF1REGFRLCKKDR | |
| SCHEMBL17631140 | 0.83 | EPHB4 (0.52) | EPHB4IGF1RKDRAURKBCDK2 | |
| SCHEMBL6481885 | 0.83 | EPHB4 (0.51) | EPHB4IGF1REGFRMAPTGAA | |
| SCHEMBL6496889 | 0.81 | EPHB4 (0.49) | EPHB4IGF1REGFRMAPTGAA | |
| SCHEMBL1390943 | 0.80 | MAPT (0.71) | EGFRMAPTGAANPC1RAB9A | |
| SCHEMBL1131631 | 0.79 | IGF1R (0.58) | EPHB4IGF1RABCG2EGFRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1218360-B1 | TRIAZINE KINASE INHIBITORS | AMGEN INC (US) | 2008-05-28 | — | — | EP | disclosed |
| US-7074789-B2 | Kinase inhibitors | AMGEN INC. (US) | 2006-07-11 | — | — | US | disclosed |
| US-6881737-B2 | Substituted triazinyl acrylamide derivatives and methods of use | AMGEN INC. (US) | 2005-04-19 | — | — | US | disclosed |
| US-6864255-B2 | Substituted triazinyl amide derivatives and methods of use | AMGEN INC. (US) | 2005-03-08 | — | — | US | disclosed |
| US-20040116388-A1 | triazine compoound inhibitors of enzymes that catalyze phosphoryl transfer and/or that bind ATP/GTP nucleotides | AMGEN INC. | 2004-06-17 | — | — | US | disclosed |
| US-20030139416-A1 | Substituted triazinyl acrylamide derivatives and methods of use | AMGEN INC. | 2003-07-24 | — | — | US | disclosed |
| US-20030087908-A1 | Substituted triazinyl amide derivatives and methods of use | AMGEN INC. | 2003-05-08 | — | — | US | disclosed |
| EP-1218360-A1 | TRIAZINE KINASE INHIBITORS | Amgen Inc., (US) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001025220-A1 | TRIAZINE KINASE INHIBITORS | AMGEN INC. (US) | 2001-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139416-A1 | Substituted triazinyl acrylamide derivatives and methods of use | PKD1, PKD2, GLS | EPHB4 3547/4885IGF1R 3717/4885ABCG2 13/4885 |
| US-20030087908-A1 | Substituted triazinyl amide derivatives and methods of use | FLT4, FLT1, VEGFA | EPHB4 2420/4885IGF1R 1116/4885ABCG2 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.